Hematology News

WASHINGTON — Tranexamic acid administered intravenously before and after noncardiac surgery lowered the risk for life-threatening, major and critical organ bleeding compared with placebo, according to results of the POISE-3 trial.

Venous thromboembolism-related hospital readmissions after complex cancer surgery continued to increase beyond 30 days after surgery, according to a multicenter, population-based retrospective study in JAMA Surgery.

The FDA rejected Akebia Therapeutics’ anemia drug vadadustat for use in patients with chronic kidney disease, citing concerns about vascular access complications and liver toxicity.

Convalescent plasma, when administered within 9 days of symptom onset in patients with COVID-19, may reduce the risk for hospitalization, according to data published in The New England Journal of Medicine.

According to one patient undergoing treatment for sickle cell disease at University Hospitals Connor Whole Health, pain associated with the disease “feels like someone’s constantly stabbing you, but you’re not dying.”

The risk for anaphylaxis from IV iron formulations appeared low, although it varied depending on the type of treatment being administered, according to a study published in Annals of Internal Medicine.

Black women experiencing postpartum hemorrhage requiring blood transfusion were less likely to receive higher levels of antihemorrhagic intervention compared with their white counterparts.

Compared with no antiplatelet therapy, aspirin and P2Y12 inhibitors did not improve the number of organ support-free days in critically ill patients with COVID-19, according to results of the REMAP-CAP trial published in JAMA.

Valoctocogene roxaparvovec induced endogenous factor VIII production and significantly reduced bleeding and factor VIII concentrate use relative to factor VIII prophylaxis in patients with severe hemophilia A, according to study results.

Prescriptions dispensed for apixaban beyond 90 days after hospitalization resulted in a lower rate of hospitalization for recurrent venous thromboembolism compared with warfarin beyond 90 days, according to study results published in JAMA.